Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens
Screening for HCQ retinopathy is cost-effective, but delayed initiation and a reduced frequency, using solely an SD-OCT, are more cost-effective. We recommend screening with an SD-OCT and a biennial regimen after 10 years for low-risk patients, an annual regimen after 5 years for intermediate- and high-risk patients.
Authors
- Sophie te Dorsthorst
- Maarten Jacobus Postma (ORCID: https://orcid.org/0000-0002-6306-3653)
- Freekje van Asten (ORCID: https://orcid.org/0000-0002-8141-4234)
- Roel Freriks (ORCID: https://orcid.org/0000-0002-9458-1832)
- Sara W. Quist (ORCID: https://orcid.org/0000-0003-3871-4239)
- Carel B. Hoyng (ORCID: https://orcid.org/0000-0002-1358-5963)
Institutions
- University Medical Center Groningen (NL)
- Radboud University Nijmegen (NL)
- University of Groningen (NL)
- Radboud University Medical Center (NL)
- Maastricht University (NL)
- Dialyse Centrum Groningen (NL)
- University of Twente (NL)
Publication Details
- Journal
- The European Journal of Health Economics
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1007/s10198-024-01715-w
- Citations
- 2
- Primary Topic
- Drug-Induced Ocular Toxicity
- Type
- article
- Field-Weighted Citation Impact
- 1.08